From: An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis
Per-protocol set 1
Per-protocol set 2
Full analysis setc
CC
(n = 17)
LC
(n = 34)
(n = 52)
Responders, n (%)a
10 (58.8)
12 (70.6)
17 (50.0)
18 (34.6)
95% CI for percentage of respondersb
32.9, 81.6
44.0, 89.7
32.4, 67.6
22.0, 49.1